Skip to main content

Table 1 Available targeted agents in advanced gastric cancer

From: The progress of targeted therapy in advanced gastric cancer

NCT code/trial name Drugs Setting Masking Primary endpoint Arm Status Results
PhaseIIIToGA/NCT01041404 HER2 inhibitor Trastuzumab First line Double blind OS Cisplatin + fluoropyrimidine + Trastuzumab vs. Placebo Finished Positive
PhaseIIINCT01774786 Pertuzumab First line Double blind OS Trastuzumab + cisplatin + fluoropyrimidine + Pertuzumab vs. Placebo Ongoing Unknown
Phase III/IIINCT01641939 T-DM1 Second line Open label OS T-DM1 vs. Taxane Ongoing Unknown
PhaseIII TYTAN/NCT00486954 Lapatinib Second line Open label OS Lapatinib vs. Paclitaxel Finished Negative
PhaseIII LOGiC/NCT00680901 Lapatinib First line Double blind OS Capecitabine + oxaliplatin + Lapatinib vs. Placebo Finished Negative
PhaseIIIEXPAND/NCT00678535 EGFR Inhibitors Cetuximab First line Open label PFS Capecitabine and cisplatin + Cetuximab vs. Placebo Finished Negative
PhaseIIIREAL-3/NCT01234324 Panitumumab First line Open label Frequency of pT3/T4 categories after surgery EOX (epirubicin/oxaliplatin/capecitabine) Ongoing Unknown
PhaseIII AVAGAST/NCT00548548 VEGF inhibitors Bevacizumab First line Double blind OS Capecitabine + cisplatin + Bevacizumab vs. Placebo Finished Negative
PhaseIII REGARD/NCT00917384 Ramucirumab Second line Double blind OS and BSC + Ramucirumab vs. Placebo Finished Positive
PhaseIIIRAINBOW/NCT01170663 Ramucirumab Second line Double blind OS Paclitaxel + Ramucirumab vs. Placebo Ongoing Unknown
PhaseIIINCT01246960 Ramucirumab First line Double blind PFS mFOLFOX6+ Ramucirumab vs. Placebo Ongoing Unknown
PhaseIIINCT00970138 Apatinib Third line Double blind PFS Placebo vs.Apatinib Finishes Positive
PhaseIIINCT01512745 Apatinib Third line Double blind PFS placebo vs. apatinib Ongoing Unknown
PhaseIIINCT01747551 Aflibercept First line Double blind PFS mFOLFOX6 + Aflibercept vs. Placebo Ongoing Unknown
PhaseIIINCT01152645 c-MET inhibitor Tivantinib (ARQ 197) Second/Thirdline Open label DCR Tivantinib Finished Modest efficacy
PhaseIIINCT01662869 Onartuzumab First line Double blind OS mFOLFOX6 + Onartuzumab vs. Placebo Ongoing Unknown
PhaseIIIGRANITE-1/NCT00879333 m-TOR inhibitor Everolimus (RAD001) Second/third line Double blind OS Everolimus vs. Placebo Finished Negative
  1. Abbreviation: HER2 human epidermal growth factor receptor-2, OS overall survival, EGFR epidermal growth factor receptor, PFS progression free survival, VEGF vascular endothelial growth factor, BSC best supportive care, DCR disease control rate, m-TOR mammalian target of rapamycinm.